ARWR vs AZN

ARWR's Piotroski F-Score of 4/9 indicates weak financial health, with a notable debt/equity ratio of 1.24 and a lack of Altman Z-Score data, raising concerns about long-term solvency. However, the company exhibits exceptional profitability with a 75.5% ROE and 100% gross margin, supported by a staggering 10,461% YoY revenue growth. Despite a high current price of $55.05 and elevated valuation multiples (P/E: 34.41, P/S: 7.07), the stock trades at a premium due to explosive growth expectations. Analysts maintain a 'buy' consensus with a target price of $81.36, reflecting strong conviction in future upside. Insider selling activity, while bearish in sentiment, may reflect liquidity events rather than fundamental concerns.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.